JP2023547689A5 - - Google Patents
Info
- Publication number
- JP2023547689A5 JP2023547689A5 JP2023527358A JP2023527358A JP2023547689A5 JP 2023547689 A5 JP2023547689 A5 JP 2023547689A5 JP 2023527358 A JP2023527358 A JP 2023527358A JP 2023527358 A JP2023527358 A JP 2023527358A JP 2023547689 A5 JP2023547689 A5 JP 2023547689A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pah
- combination
- cancer
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2020/081143 | 2020-11-05 | ||
| PCT/EP2020/081143 WO2022096103A1 (en) | 2020-11-05 | 2020-11-05 | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
| PCT/EP2021/080822 WO2022096673A1 (en) | 2020-11-05 | 2021-11-05 | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023547689A JP2023547689A (ja) | 2023-11-13 |
| JP2023547689A5 true JP2023547689A5 (https=) | 2023-11-20 |
| JP7531707B2 JP7531707B2 (ja) | 2024-08-09 |
Family
ID=73138835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527358A Active JP7531707B2 (ja) | 2020-11-05 | 2021-11-05 | 癌を処置するためのパラアミノ馬尿酸（ｐａｈ）および放射能標識された複合体の組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230414796A1 (https=) |
| EP (1) | EP4065176B1 (https=) |
| JP (1) | JP7531707B2 (https=) |
| KR (1) | KR20230127212A (https=) |
| CN (1) | CN116981487A (https=) |
| AU (1) | AU2021375728A1 (https=) |
| DK (1) | DK4065176T3 (https=) |
| ES (1) | ES2967379T3 (https=) |
| FI (1) | FI4065176T3 (https=) |
| HU (1) | HUE065304T2 (https=) |
| PL (1) | PL4065176T3 (https=) |
| WO (2) | WO2022096103A1 (https=) |
| ZA (1) | ZA202304769B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR2022007815A1 (tr) * | 2022-05-13 | 2023-11-21 | Ege Ueniversitesi Idari Ve Mali Islerdaire Bsk | Yüksek stabi̇li̇teye ve radyoi̇şaretleme veri̇mi̇ne sahi̇p radyofarmasöti̇kler ve bahsedi̇len radyofarmasöti̇kleri̇ i̇çeren teranosti̇k ki̇t |
| CN115212322B (zh) * | 2022-06-01 | 2024-01-16 | 原子高科股份有限公司 | 一种用于放射性药物制备的冻干药盒及其制备方法 |
| TW202540073A (zh) * | 2023-11-30 | 2025-10-16 | 大陸商輻聯科技香港有限公司 | 靶向ｓｓｔｒ受體的放射性化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006176427A (ja) | 2004-12-21 | 2006-07-06 | Geno Membrane:Kk | エストロン３硫酸トランスポーター活性の阻害剤 |
| US20070025910A1 (en) | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| US20070166774A1 (en) * | 2006-01-17 | 2007-07-19 | Groman Ernest V | Functional immunoassay |
| US20100255117A1 (en) * | 2007-04-06 | 2010-10-07 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| AU2012294639B2 (en) | 2011-08-05 | 2017-10-26 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| PL2970345T3 (pl) | 2013-03-15 | 2019-12-31 | Cancer Targeted Technology Llc | Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA |
| EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CA3060143A1 (en) | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
| WO2020108753A1 (en) | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| WO2020224780A1 (en) * | 2019-05-08 | 2020-11-12 | ITM Isotopen Technologien München AG | Para-aminohippuric acid (pah) as a renal protective substance |
-
2020
- 2020-11-05 WO PCT/EP2020/081143 patent/WO2022096103A1/en not_active Ceased
-
2021
- 2021-11-05 AU AU2021375728A patent/AU2021375728A1/en active Pending
- 2021-11-05 WO PCT/EP2021/080822 patent/WO2022096673A1/en not_active Ceased
- 2021-11-05 JP JP2023527358A patent/JP7531707B2/ja active Active
- 2021-11-05 FI FIEP21810930.4T patent/FI4065176T3/fi active
- 2021-11-05 PL PL21810930.4T patent/PL4065176T3/pl unknown
- 2021-11-05 HU HUE21810930A patent/HUE065304T2/hu unknown
- 2021-11-05 KR KR1020237018786A patent/KR20230127212A/ko active Pending
- 2021-11-05 DK DK21810930.4T patent/DK4065176T3/da active
- 2021-11-05 EP EP21810930.4A patent/EP4065176B1/en active Active
- 2021-11-05 ES ES21810930T patent/ES2967379T3/es active Active
- 2021-11-05 CN CN202180084046.4A patent/CN116981487A/zh active Pending
- 2021-11-05 US US18/035,662 patent/US20230414796A1/en active Pending
-
2023
- 2023-04-25 ZA ZA2023/04769A patent/ZA202304769B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112074526B (zh) | 作为治疗性放射性药物的177Lu-DOTA-HYNIC-iPSMA | |
| JP2023547689A5 (https=) | ||
| JP2022532187A5 (https=) | ||
| Ferrier et al. | An appendix of radionuclides used in targeted alpha therapy | |
| García-Garayoa et al. | A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours | |
| EP3486249B1 (en) | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | |
| KR102934560B1 (ko) | 신장 보호 물질로서의 파라-아미노히푸르산(pah) | |
| US20240374732A1 (en) | Stable formulations for radionuclide complexes | |
| FI4065176T3 (fi) | Para-aminohippurihapon (PAH) ja radioaktiivisesti merkittyjen kompleksien yhdistelmä syövän hoitoon | |
| Zhang et al. | Comparison of radionuclide drug conjugates with boron neutron capture therapy: an overview of targeted charged particle radiation therapy | |
| Eychenne et al. | Overview of the most promising radionuclides for targeted alpha therapy: The “hopeful eight.” Pharmaceutics. 2021; 13: 906 | |
| US20250009911A1 (en) | DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN | |
| Orsini et al. | Radiopharmaceuticals for single-photon emission imaging and for therapy | |
| Gotthardt et al. | Nuclear medicine imaging and therapy of neuroendocrine tumours | |
| JP2023552383A5 (https=) | ||
| RU2804349C2 (ru) | Парааминогиппуровая кислота (паг) как вещество для защиты почек | |
| Liu et al. | Biological evaluation of [99mTc] Tc-labeled Buthus martensii Karsch Chlorotoxin peptide for glioma imaging | |
| Deshayes et al. | Anti-MISRII radiolabeled antibodies: new tools for a theranostic approach in ovarian cancer | |
| Cohen et al. | Moving Forward: Expected Opportunities for the Development of New Therapeutic Agents | |
| Hasegawa et al. | Radiotherapeutic Applications | |
| HK40033441B (zh) | 作为治疗性放射性药物的177lu-dota-hynic-ipsma | |
| HK40084129A (en) | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | |
| Schweinsberg | Novel 99mTc-labeled bombesin analogues with improved pharmacokinetics for targeting of gastrin-releasing-peptide receptor-positive tumors | |
| HK40065088A (en) | Para-aminohippuric acid (pah) as a renal protective substance | |
| HK40065088B (en) | Para-aminohippuric acid (pah) as a renal protective substance |